An Open-labelled, Randomized Phase II Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With GBM Measured as Progression Free Survival Compared to Avastin/Irinotecan
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2016
Price : $35 *
At a glance
- Drugs Cancer vaccine-ALECSAT (Primary) ; Bevacizumab; Irinotecan
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors CytoVac
- 16 Jun 2015 Planned End Date changed from 1 Mar 2017 to 1 Sep 2015 as per ClinicalTrials.gov.
- 16 Jun 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 24 Feb 2014 New trial record